E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study
In heavily pretreated patients with advanced solid tumors, E7386 demonstrated a manageable safety profile and a dose-dependent PK profile. PRs were noted in patients with small bowel carcinoma or desmoid tumor.
Authors
- A. Kawazoe
- Tatsuo Kimura (ORCID: https://orcid.org/0000-0002-5816-7132)
- Jun Sato (ORCID: https://orcid.org/0000-0001-9249-6522)
- T. Yokota
- Satoshi Nagao (ORCID: https://orcid.org/0000-0002-8855-4627)
- Shinji Itoh
- N. Hayata
- K. Shitara
- Noboru Yamamoto (ORCID: https://orcid.org/0000-0002-0787-2851)
- Toshiyuki Tamai (ORCID: https://orcid.org/0000-0002-7531-2274)
- K. Yamazaki
- S. Yamamuro
- Saori Mishima (ORCID: https://orcid.org/0000-0002-5922-1487)
- Eiji Oki (ORCID: https://orcid.org/0000-0002-9763-9366)
- Yuki Katsuya (ORCID: https://orcid.org/0000-0002-2127-3601)
- S. Kondo
Institutions
- Kyushu University (JP)
- Shizuoka Cancer Center (JP)
- National Cancer Center (US)
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
- Eisai (Japan) (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105893
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00